





Novartis: summary of recent CAR-T/IO business alliances/deals

Company	Partner	Date	Area	Details
	Cryoport [CRYX]	July 25 th 2017	Cryogenic logistics support	3 year agreement, financial terms not disclosed
	Oxford Biomedica	July 6 th 2017	Commercial/clinical supply of lentiviral vectors LentiVector®	\$10m upfront, 3 yrs*, potentially \$100m, undisclosed royalties
	Celyad	May 2 nd 2017	Novartis granted non-exclusive^ license for allogeneic TCR-deficient	Celyad eligible to receive payments (incl upfront) totalling \$96m. Single digit royalties also available on associated products
	Surface Oncology	January 11 th 2016	4 pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites	

*extendable to 5 years

^option to convert to exclusive license

IO = immuno-oncology

About iOnco Analytics:

iOnco Analytics is a subdivision of VacZine Analytics, a world leading supplier of vaccine market analyses

With our product lines:

- ① MarketVIEW
- ① ExpertREACT


Our role is to define market potential and strategy of new cancer immunotherapies

Disclaimer

All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.





iOnco Analytics

Immunotherapeutic market strategy...

www.iOnco-analytics.com

Carlton House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
Tel +44 (0) 1279 813155
E-mail: info@ionco-analytics.com